气候变化领域集成服务门户(CCPortal): A high-throughput microfluidic nanoimmunoassay for detecting anti–SARS-CoV-2 antibodies in serum or ultralow-volume blood samples

CCPortal

DOI	10.1073/PNAS.2025289118
	A high-throughput microfluidic nanoimmunoassay for detecting anti–SARS-CoV-2 antibodies in serum or ultralow-volume blood samples
	Swank Z.; Michielin G.; Yip H.M.; Cohen P.; Andrey D.O.; Vuilleumier N.; Kaiser L.; Eckerle I.; Meyer B.; Maerkl S.J.
发表日期	2021
ISSN	00278424
卷号	118 期号:18
英文摘要	Novel technologies are needed to facilitate large-scale detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific antibodies in human blood samples. Such technologies are essential to support seroprevalence studies and vaccine clinical trials, and to monitor quality and duration of immunity. We developed a microfluidic nanoimmunoassay (NIA) for the detection of anti–SARS-CoV-2 IgG antibodies in 1,024 samples per device. The method achieved a specificity of 100% and a sensitivity of 98% based on the analysis of 289 human serum samples. To eliminate the need for venipuncture, we developed low-cost, ultralow-volume whole blood sampling methods based on two commercial devices and repurposed a blood glucose test strip. The glucose test strip permits the collection, shipment, and analysis of 0.6 µL of whole blood easily obtainable from a simple finger prick. The NIA platform achieves high throughput, high sensitivity, and specificity based on the analysis of 289 human serum samples, and negligible reagent consumption. We furthermore demonstrate the possibility to combine NIA with decentralized and simple approaches to blood sample collection. We expect this technology to be applicable to current and future SARS-CoV-2 related serological studies and to protein biomarker analysis in general. © 2021 National Academy of Sciences. All rights reserved.
英文关键词	High-throughput serology; Microfluidics; Nanoimmunoassay; SARS-CoV-2
语种	英语
来源期刊	Proceedings of the National Academy of Sciences of the United States of America
文献类型	期刊论文
条目标识符	http://gcip.llas.ac.cn/handle/2XKMVOVA/181164
作者单位	Institute of Bioengineering, School of Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, 1015, Switzerland; Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals, Geneva University, Geneva, 1205, Switzerland; Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals, Faculty of Medicine, Geneva, 1205, Switzerland; Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, Faculty of Medicine, Geneva, 1205, Switzerland; Center for Emerging Viral Diseases, Geneva University Hospitals, Faculty of Medicine, University of Geneva, Geneva, 1205, Switzerland; Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, 1205, Switzerland
推荐引用方式 GB/T 7714	Swank Z.,Michielin G.,Yip H.M.,等. A high-throughput microfluidic nanoimmunoassay for detecting anti–SARS-CoV-2 antibodies in serum or ultralow-volume blood samples[J],2021,118(18).
APA	Swank Z..,Michielin G..,Yip H.M..,Cohen P..,Andrey D.O..,...&Maerkl S.J..(2021).A high-throughput microfluidic nanoimmunoassay for detecting anti–SARS-CoV-2 antibodies in serum or ultralow-volume blood samples.Proceedings of the National Academy of Sciences of the United States of America,118(18).
MLA	Swank Z.,et al."A high-throughput microfluidic nanoimmunoassay for detecting anti–SARS-CoV-2 antibodies in serum or ultralow-volume blood samples".Proceedings of the National Academy of Sciences of the United States of America 118.18(2021).